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The link between sex steroids and the development and growth of breast cancer has proved to be an invaluable clue for advances in
the prevention and treatment of breast cancer. The identification of the oestrogen receptor (ER) not only allowed advances in the
molecular endocrinology of oestrogen action, but also provided a target for antioestrogenic therapeutic agents. However, the
application of long-term or indefinite treatment regimens has consequences for the breast cancer. New forms of resistance, based
upon enhanced cellular survival networks independent of ER and the suppression of apoptotic mechanisms, develop and then evolve.
Remarkably, low concentrations of oestrogen collapse survival pathways and induce apoptosis in completely antihormonally
refractory breast cancer. However, recurrent oestrogen-stimulated disease is again sensitive to antihormonal therapy. The novel
reapplication of the ER as a therapeutic target for apoptosis is emerging as a new strategy for the long-term targeted maintenance
treatment of breast cancer, and in formulating a targeted strategy for endocrine independent cancer.
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There is an expanding clinical database that implicates oestrogen
and progestins (hormone replacement therapy, HRT) in the
development and growth of breast cancer. Evidence to support
this conclusion comes from two major clinical sources: clinical
studies of HRT, initially designed to determine the benefits of
replacement approaches on postmenopausal women’s health
(Writing Group for the Women’s Health Initiative Investigators,
2002; Million Women Study Collaborators, 2003) and the
successful clinical strategy of treating breast cancer by blocking
oestrogen action.
The Million Woman Study provides powerful (Million Women
Study Collaborators, 2003) information about the actual impact of
HRT on the incidence of breast cancer. A total of 1084110 UK
women aged 50–64 years were recruited to determine the
association of HRT use with breast cancer incidence and death.
It is estimated that 10 years use of HRT produces 19 additional
breast cancers per 1000 users. These data extrapolate to an
estimated total of an excess of 15000 breast cancers associated
with HRT over the past decade in the UK.
In contrast to the effects of hormone replacement on the
incidence of breast cancer, the use of either an antioestrogen,
tamoxifen, to block the action of oestrogen in breast cancer
(EBCTCG, 1998), or an aromatase inhibitor, to prevent oestrogen
synthesis in postmenopausal patients (ATAC Trialist Group, 2002),
is effective, and is considered to be the standard treatment strategy
for breast cancer. Indeed, the concept of antioestrogenic interven-
tions has been advanced with the reduction of risk from breast
cancer by using tamoxifen (Cuzick et al, 2003) or raloxifene
(Cummings et al, 1999), as well as suggestions for the evaluation of
a number of aromatase inhibitors as chemopreventives in high-
risk postmenopausal populations.
To the casual observer, the clinical evidence appears to
demonstrate that oestrogen is detrimental to women’s health and
especially implicated in breast cancer development and growth.
However, there have been consequences to current antihormonal
strategies and we will propose new concepts about antihormonal
drug resistance in breast cancer, which can be rapidly incorporated
into the treatment plan. In otherwords, there are now opportu-
nities to kill sensitised tumour cells with oestrogen and advance a
new innovation in therapeutics.
CLASSICAL CONCEPT OF TUMOUR TARGETING
The discovery of the ER as a critical component of the oestrogen
signal-transduction pathway in target tissues (Jensen and Jacob-
son, 1962) and the utilisation of this knowledge as a target for
antihormonal therapy in breast cancer (Jensen and Jordan, 2003)
improved the survival prospects for millions of breast cancer
patients. However, the advance with antioestrogens occurred not
only because of targeting the ER, to prevent oestrogen-stimulated
tumour growth, but also because of the application of the
appropriate duration of treatment. During the 1970s, when
tamoxifen was initially being evaluated as an adjuvant therapy in
patients, laboratory studies demonstrated that longer durations of
complete antihormonal therapy were likely to provide more
benefit for patients than shorter durations of therapy (Lerner
and Jordan, 1990). At the time, the majority of clinical trials elected
to use 1 year of therapy, because there was a sincere concern that
longer durations would enhance the possibility of premature drug
resistance. Following the methodical evaluation of randomised
clinical trials, conducted over the past 20 years, it is now clear that
1 year of adjuvant tamoxifen is only minimally effective, but 5
years of tamoxifen produces an increase in disease-free and overall
survival (EBCTCG, 1998). The use of long-term (5 years) adjuvant
antihormone therapy is now standard for the treatment of breast
cancer therapy.
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increasing the duration of treatment from 5 to 10 years have been
disappointing (Fisher et al, 2001). It appears there is a reduced
effectiveness of the antitumour actions of tamoxifen, possibly
because of developing drug resistance, but also an increase in
oestrogenic side effects such as endometrial cancer and blood
clots. In contrast, the use of a non-crossresistant aromatase
inhibitor as a continuing adjuvant after 5 years of adjuvant
tamoxifen reduces the incidence of recurrence and contralateral
breast cancer by nearly 50% compared to no treatment (Goss et al,
2003). Thus, the cycling of antihormonal strategies can maintain
patients disease free for long periods.
Clinical trials of adjuvant tamoxifen therapy also provide an
invaluable insight into the appropriate duration of treatment
necessary for the evaluation of the prevention of primary breast
cancer. The Oxford Overview of clinical trials (EBCTCG, 1998)
demonstrated that 1 and 2 years of adjuvant tamoxifen produce
only modest decreases in contralateral breast cancers, but 5 years
of adjuvant tamoxifen reduce contralateral breast cancer by 50%.
These data are consistent with the findings of the NSABP P-1 trial
that 5 years of tamoxifen reduce the incidence of invasive and
noninvasive breast cancer in high-risk pre- and postmenopausal
women, by approximately 50% (Fisher et al, 1998). Currently, in
the United States, appropriately selected high-risk women can use
a course of 5 years of tamoxifen to reduce their risk of breast
cancer.
The treatment of breast cancer has changed dramatically during
the past 15 years, with all patients now receiving long-term
antihormonal therapies, whether it is tamoxifen (EBCTCG, 1998),
aromatase inhibitors (ATAC Trialists’ Group, 2002), or LHRH
superagonists plus tamoxifen (Emens and Davidson, 2003).
However, the intense laboratory study of nonsteroidal antioestro-
gens led to the recognition of selective oestrogen receptor
modulation (SERM) (Jordan, 2001), and the idea that SERMs
could be used to treat and prevent osteoporosis but prevent breast
cancer as a beneficial side effect (Lerner and Jordan, 1990).
Raloxifene, a molecule related to tamoxifen, is used to treat and
prevent osteoporosis with a reduction of breast cancer (Cummings
et al, 1999). In the wake of the controversy surrounding the
negative effects of HRT, there are new opportunities to develop
novel SERMs to address the prevention of osteoporosis, coronary
heart disease (CHD) and breast cancer. Raloxifene is currently
being evaluated for the prevention of breast cancer and CHD in
high-risk postmenopausal women, so it could become the first
multifunctional medicine.
Despite the fact that SERMs introduce a new dimension into
therapeutics for the prevention of osteoporosis and CHD, the
question of unlimited treatment durations with SERMs will have
consequences for the natural history of breast cancer. Early
reductions in the incidence of ER-positive disease (Fisher et al,
1998; Cummings et al, 1999) will potentially result in SERM-
resistant breast cancers, thereby confronting the oncologist with
unanticipated and complex treatment decisions in an increasing
proportion of women. However, laboratory studies have estab-
lished a new understanding of SERM resistance that could
potentially convert breast cancer from an acute to a chronic,
controllable disease.
CHANGES IN THE UNDERSTANDING OF
ANTIHORMONE RESISTANCE
During the past 20 years, there has been an important change in
the understanding of drug resistance to the antioestrogen
tamoxifen. In the early 1980s, tamoxifen was anticipated to be
effective in ER-positive breast cancers, but ineffective in ER-
negative disease. Resistance to tamoxifen would develop because
the ER-positive tumour cells would be controlled, but eventually
these would be overwhelmed by the outgrowth of ER-negative
breast cancer cells (Figure 1A). However, this model was not
consistent with the known clinical observation that select patients
with metastatic breast cancer could be maintained on successive
endocrine therapies for prolonged periods.
It is now clear that there are two types of drug resistance to
tamoxifen: intrinsic resistance, where the tumour is either ER
negative or ER positive with pre-existing enhanced survival
pathways (HER2/neu plus a coactivator molecule AIB1) (Osborne
et al, 2003), and acquired resistance where an ER-positive tumour
that initially responds to treatment now becomes tamoxifen-
stimulated and grows in response to either tamoxifen or oestrogen.
An ER-positive breast tumour that initially responds to an SERM
eventually develops acquired resistance by clonal selection for
increased cell surface signalling that subverts the SERM ER
complex through enhanced phosphorylation cascades. The labora-
tory description of acquired resistance forms the scientific basis
for the understanding of current therapeutic interventions with
aromatase inhibitors or fulvestrant as second-line agents, following
the development of clinical resistance to tamoxifen. Aromatase
inhibitors block oestrogen synthesis and fulvestrant destroys the
ER to prevent the growth of breast cancers with acquired
tamoxifen resistance. However, despite the remarkable investment
in a broad range of antihormonal therapies, the actual advance in
improved survival and reduced side effects has been modest.
The successful control of breast cancer with antihormonal
therapy requires years of successive treatments. An obstacle to the
progress in therapeutics is a clear understanding of the changes
that occur in the breast cancer cell, as a consequence of exhaustive
antihormonal therapies. It is presumed that the cancer cell must
create a sophisticated survival network and suppress the natural
process of apoptosis to subvert the continuous inhibitory signal
through the ER. Until recently, no laboratory models replicated the
former clinical scenario, but the deficiencies in our knowledge are
being corrected.
Drug resistance to tamoxifen evolves through three phases:
Phases I and II both require tamoxifen, or a related SERM
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Figure 1 The evolution of antihormonal resistance. (A) About 20 years
ago, it was believed that oestrogen receptor-positive (ERþ) tumours
would usually be expected to respond to oestrogen withdrawal or a
selective oestrogen receptor modulator (SERM) such as tamoxifen, but
eventually resistance would occur because ER  cells would overgrow the
tumour. (B) Emerging laboratory and clinical evidence suggests that SERM
resistance evolves from acquired resistance (Phase I) to Phase II, where any
SERM will maintain growth, whereas, unliganded ER does not provoke
growth. However, oestrogen at physiological levels causes rapid apoptosis.
In Phase III, tumours are completely resistant to all antihormonal therapies
and grow spontaneously. Nevertheless, physiological concentrations of
oestrogen causes rapid apoptosis.
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positive tumour is refractory to all antihormonal therapies and
growth is SERM independent (Jordan et al, 2003) (Figure 1B).
Remarkably, the response of the breast tumour to oestrogen
during the evolution of drug-resistance changes dramatically, from
initially being growth stimulatory to becoming completely
inhibitory after 5 years of antihormonal therapy. Apoptosis is
initiated in response to minute concentrations of oestradiol, which
results in dramatic tumour regression in heterotransplanted
athymic mice. When this phenomenon was first noted and
reported in the early 1990s (Wolf and Jordan, 1993), it was
suggested that a woman’s own oestrogen actually destroyed the
micrometastases that were presensitised by 5 years of tamoxifen
treatment. In otherwords, stopping tamoxifen at a critical time (5
years) was responsible for the long-term survival statistics. While
the concept may have some veracity, the knowledge that minute
concentrations of oestrogen can have a dramatic effect on tumour
cell death could have important clinical implications for treatment.
Indeed, a clear understanding of the mechanism of Phase II and III
resistance is becoming increasingly important for the treatment of
metastatic breast cancer.
The current focus on exhaustive antiendocrine therapy may in
fact be disadvantageous for patients. The antitumour action of
oestrogen in Phase II tamoxifen resistance can paradoxically be
reversed by fulvestrant (Osipo et al, 2003). In otherwords,
oestradiol causes rapid tumour regression, fulvestrant causes
tumourstasis, but a combination of oestradiol and fulvestrant
causes robust tumour growth. If Phase II or III drug resistance to
tamoxifen can be shown to occur in patients, then an oestrogen-
rich environment would subvert the actions of fulvestrant.
Obviously, one could enhance the probability of a response to
fulvestrant by administering an aromatase inhibitor, but perhaps
oestrogen should be pursued as a targeted alternative. To advance
this idea, it would be valuable to examine whether the observations
in the laboratory with the evolution of tamoxifen drug resistance
apply to other SERMs and to breast cancer cells that have adapted
to oestrogen deprivation, that is, as an expression of resistance to
aromatase inhibitors.
EXPANSION OF THE CONCEPT OF
OESTROGEN-INDUCED APOPTOSIS
Song et al (2001) were the first to demonstrate that oestradiol
causes apoptosis in breast cancer cells that have been adapted to
grow in an oestrogen-free environment for prolonged periods.
These investigators suggested that their data provided an
explanation for the effectiveness of high-dose diethylstilboestrol
formally used to treat breast cancer in elderly postmenopausal
women, that is, women who were 10–25 years after menopause.
Thus, a switch occurs in the cancer cell from oestrogen stimulating
growth to oestrogen causing cell death after prolonged oestrogen
deprivation. However, and perhaps more importantly, the
apoptotic effect occurs with low concentrations of oestradiol. We
illustrate the principle in Figure 2B by comparing and contrasting
the action of oestradiol in wild-type breast cancer cells and an ER-
positive progesterone receptor-negative, oestrogen-deprived clone
referred to as MCF-7 5C (Jiang et al, 1992). Of interest is the
observation that alterations in the media can enhance the actions
of oestradiol as an apoptotic agent. Clearly, this is an area of
research activity worthy of pursuit as the proposed therapeutic use
of long-term aromatase inhibition can potentially reconfigure the
cellular response to oestrogen.
The other relevant clinical scenario is the response of occult
breast cancer cells to indefinite raloxifene administration for the
treatment and prevention of osteoporosis. Long-term culture of
breast cancer cells in 1mM raloxifene results in adaptation of cell-
survival mechanisms and raloxifene resistance. Transplantation of
cells into athymic mice demonstrates Phase II SERM resistance;
tamoxifen or raloxifene stimulates growth, no treatment (no ER
binding ligand) results in no growth, but oestradiol causes
apoptosis and rapid tumour regression (Liu et al, 2003). Thus, a
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Figure 2 Oestradiol inhibits the growth of MCF-7:5C cells and induces
apoptosis. MCF-7:5C cells were cloned from wild-type MCF-7:WS8 cells
following long-term growth (B1 year) in oestrogen-free RPMI medium
containing 10% (vv
 1) dextran charcoal-stripped (DCC) foetal bovine
serum (FBS), 2mM glutamine, 100Uml
 1 penicillin-streptomycin, 6ngml
 1
bovine insulin, and 1  nonessential amino acids. (A) For DNA assays,
MCF-7:5C cells were seeded into 12-well plates at a density of B20000
cells per well in RPMI medium. The cells were left for 24h to acclimatise,
and then treated with 0.1, 1, or 10nM oestradiol (E2) for a total of 6 days,
with the control cells receiving o0.1% ethanol vehicle. Cells were re-fed on
days 3 and 5. Total DNA (mg) per well was used to measure cell growth.
The data represent the average of five separate experiments. (B)
Apoptotic cells were identified/quantified by double staining with
recombinant FITC-conjugated annexin V and propidium iodide (PI), using
the Annexin V-FITC kit (Immunotech, Beckman Coulter). For experiments,
MCF-7:WS8 and MCF-7:5C cells were seeded in 100mm plates at a
density of 1 10
6 per plate in either oestrogen-free RPMI medium
containing 10% DCC stripped fetal bovine serum (SFS) or MEM containing
5% DCC stripped calf serum (SCS). The cells were left for 24h to
acclimatise and then treated with either 1nM E2 or less than 0.1% ethanol
vehicle (control) for 72h. Data shown represent three separate
experiments. It should be noted that oestradiol treatment of MCF-
7:WS8 cells in oestrogen-free MEM media containing 5% SCS did not have
any significant effect on apoptosis (data not shown).
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laboratory to discover mechanisms that could be targeted and
amplified.
MOLECULAR MECHANISMS
The target site-specific actions of SERMs are not well understood,
but there is an emerging understanding of the modulation of the
SERM ER complex in breast cancer (Figure 3). Antioestrogenic
action appears to be dominant in a cancer cell with no cell surface
signalling, and the SERM ER complex binds preferentially to
corepressor molecules to prevent gene activation and cell
replication (Figure 3A). In contrast, the oestrogen-like actions of
an SERM become dominant in acquired resistance when cells are
selected with enhanced cell surface signalling, reduced corepres-
sors but increased coactivator molecules (Figure 3B). This
molecular mechanism could serve as a working model for Phase
I drug resistance. It is plausible that the subsequent evolution of
drug resistance into Phase II results from an enhanced sophistica-
tion in establishing survival pathways during continuing selection
in an oestrogen-deprived environment. Ultimately, the ER appears
to become redundant for growth in Phase III drug resistance
(Jordan et al, 2003). However, it is the remarkable switch from
oestrogen-stimulated growth in breast cancer to oestrogen-
stimulated death that merits investigation. Song et al (2001) first
focused attention on the fas, fas ligand pathway as a potential
mechanism of oestrogen-induced apoptosis in oestrogen-deprived
breast cancer cells. Study of molecular mechanisms for oestrogen-
induced tumour regression have recently been extended with the
demonstration that oestrogen simultaneously collapses survival
mechanisms (HER2/neu NFkB) in the Phase II SERM-resistant
tumour, and enhances the expression of the fas receptor (Liu et al,
2003; Osipo et al, 2003) (Figure 3C,D). Clearly, much needs to be
done to understand the new molecular endocrinology of oestrogen
action, but the knowledge now creates opportunities for novel
applications in therapeutics.
CLINICAL CORRELATIONS
Current clinical practice is focused on the premise that oestrogen
is the principal growth stimulator in select ER-positive
breast cancers. The application of this principle over the past
30 years has been at the forefront of targeted therapeutics, and
has undoubtedly saved lives. However, clinical clues are emerging
that the practice of exhaustive antihormonal therapy is not
always appropriate, and useful palliation can occur with an
application of the obsolete modality of pharmacological oestrogen
treatment (diethylstilboestrol, 5mg three times a day). Renewed
interest in re-treating endocrine refractory disease with high-
dose oestrogen has demonstrated improvement in the anecdotal
patient (Ingle, 2002) and remarkable responses in metastatic
breast cancer patients treated exhaustively with antihormonal
therapies (Lonning et al, 2001). Out of 32 evaluable patients,
four had complete response, six had partial response and two
had stable disease. These encouraging data require confirmation,
before any change in medical practice can be recommended,
but for the individual patient with completely refractory disease
the potential for palliation is clear. More importantly, there is
now a renewed conversation between the laboratory and the clinic
that offers opportunities not only to enhance the duration of
responses based on retargeting the ER, but also to improve the
proportion of response rates, based on an enhanced understanding
of the survival and death pathways that could potentially be
manipulated.
OPPORTUNITIES FOR TARGETING OESTROGEN TO
THE TUMOUR
Professor Paul Erlich established the foundation for targeted
therapeutics by describing the successful process for treating
infectious disease. An effective treatment is based on selective
toxicity to destroy the disease and not the patient. To achieve that
goal, an appropriate laboratory model for the disease in question
should be used to identify active synthetic molecules that will
selectively destroy the disease in vivo under laboratory conditions.
The successful chemotherapeutic candidate can subsequently be
evaluated in clinical trials to establish ‘real world’ efficacy and
selectivity. The process has been remarkably successful during the
past Century, with the development of a diverse range of
antibacterial agents and drugs to either prevent or palliate parasitic
disorders. Unfortunately, the realisation of the goal of targeting
cancer selectively has, until recent times, remained elusive. Not
that there has not been a sincere attempt to achieve the goal. About
100 years ago, Professor Paul Erhlich was the first to apply the
principles of chemotherapeutic drug discovery to cancer cures. His
approach was not successful. He declared, ‘I have wasted 15 years
of my live in experimental cancer research’, the year before he died
on 20th August 1915.
What has become increasingly clear is that establishing target
site specificity is not simple, especially in cancer, and that, for the
Figure 3 The development of tamoxifen (TAM)-resistant breast cancer
and the changing role of oestradiol (E2) in the life and death of ER-positive
cancer cells. (A)E 2-stimulated growth is inhibited by the use of an
aromatase inhibitor to block oestrogen synthesis or TAM to block the ER
and prevent oestrogen-stimulated gene transcription. Optimal antioestro-
genic effects occur in the absence of pre-existing cell surface signalling
mechanisms. (B) Prolonged use of TAM promotes an increase in HER2/
neu cell surface signalling that creates a survival pathway phosphorylating
the TAM ER complex and coactivator proteins. The transcription complex
becomes activated to enhance gene activation and TAM-stimulated
growth. If this is Phase I resistance, then oestrogen will also promote
growth; so an aromatase inhibitor is an appropriate second-line therapy. If it
is Phase II resistance, E2 causes apoptosis. (C) In Phase II tamoxifen
resistance, the E2 ER complex collapses the survival mechanisms by
dramatically reducing the level of cell surface signalling by preventing HER2/
neu mRNA transcription and the nuclear level of NFkB, a transcription
factor. (D) In Phase II tamoxifen resistance, the E2 ER complex also
enhances the synthesis of Fas receptor mRNA and protein which, in the
presence of Fas ligand (FasL) activates caspase 8 and a cascade of events
resulting in apoptosis. These figures are summaries of the mechanisms
described in Osipo et al (2003) and Liu et al (2003).
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consequences of launching an attack that is not complete – drug
resistance. The success in targeting breast cancer initially
developed slowly by the reinvention and retargeting of
existing molecules that had not succeeded in their primary
applications. Tamoxifen, discovered in a fertility-control program,
was reinvented as a breast cancer drug and subsequently targeted
to the ER (Jordan, 2003). Raloxifene, discovered in a breast
cancer program and targeted to the ER, was reinvented
as a preventive for osteoporosis with breast and uterine
safety. After 30 years of clinical usage, the ubiquitous application
of SERMs has now provided clues to progress by retargeting
the ER with oestrogen in SERM-resistant disease. However,
rather than returning to the therapeutic modality of the
1960s by reintroducing high-dose oestrogen therapy for a
few select patients, the new knowledge emerging from the
laboratory now creates novel scientific and clinical opportunities
to target the ER and extend response rates, cycle antihormonal
therapies, enhance response rates and determine the
precise molecular mechanism of ER-mediated apoptosis, so
the knowledge could potentially be exported to kill ER-negative
tumour cells.
There are at least two dimensions to consider when applying
the targeted action of oestrogen to the tumour: the nature
of the oestrogen ER complex and the length of time that oestrogen
must be administered to initiate the apoptotic cascade. The ER
can bind an enormous range of ligands with diverse shapes
and structures. To date, laboratory and clinical studies of ER-
mediated apoptosis have only used either oestradiol or
DES. However, recent studies of the molecular biology of oestrogen
action have defined two classes of ER complex. This is because
the shape of the ligand preprograms the actual external shape
of the ER complex (Bentrem et al, 2003). The planar oestrogens,
oestradiol, DES and the phyto-oestrogens genistein and
coumestrol are class I oestrogens that rely on helix 12 in the
ligand-binding domain to seal the oestrogen molecule into
the hydrophobic pocket (Bentrem et al, 2003). This causes
activating function (AF) 2 to be triggered, and synergise
with AF-1 at the other end of the complex during the formation
of a gene transcription complex. In contrast, a nonplanar
oestrogen binds in the ligand binding domain, but prevents
activation of AF-2. Helix 12 cannot seal the ligand in the
hydrophobic pocket, and the transcription complex occurs
through the triple site interaction of AF-1, D351 and select acidic
amino acids in helix 12 (Bentrem et al, 2003). The comparative
testing of a range of phytoestrogens and the active constituents of
conjugated equine oestrogens, equilin and equilenin, for their
activity as apoptotic agents in Phase II and III antihormone drug
resistance, will establish which types of low-dose oestrogen could
be used in clinical studies.
An important laboratory observation is that the apoptotic
response of SERM-resistant breast cancer occurs, not
with pharmacologic doses of oestrogen but physiologic oestradiol
in the postmenopausal range (Yao et al, 2000). The majority
of SERM-resistant tumours regress completely, but the few
that regress but regrow are again completely responsive to
tamoxifen that prevents oestradiol-stimulated growth. Although
the precise nature of switching mechanisms from tamoxifen
stimulated and oestrogen killing to oestrogen stimulated and
tamoxifen blocking has not been established, recent studies
(Liu et al, 2003; Osipo et al, 2003) show that oestradiol rapidly
collapses the survival mechanisms (HER2/neu and NFkB)
that support tamoxifen-stimulated growth. It is therefore
reasonable to speculate that surviving cells are selected to be
exclusively oestrogen responsive but which do not possess
the survival mechanisms to support tamoxifen-stimulated
growth. Thus, tamoxifen would again express antitumour
actions on oestradiol-stimulated tumour growth (Yao et al,
2000). Based on the laboratory findings (Yao et al, 2000),
a clinical program should be initiated to determine the therapeutic
value of short or extended conjugated equine oestrogen- or
high phytoestrogen- containing diets. The results of the
studies could establish new standards of clinical care initially
to extend the effectiveness of antihormonal therapies for meta-
static breast cancer and, subsequently, the consideration of
rotating adjuvant antihormones with an ‘oestrogen purge’ to
improve survival through extending the duration of disease-free
survival.
The next two challenges have the potential to expand the value
of the developing knowledge on ER-induced cellular apoptosis.
Half of the ER-positive tumours do not respond to antihormonal
therapy; therefore, any strategy to target the ER in endocrine
refractory tumours would ultimately double response rates in
breast cancer. Endocrine refractory disease appears to have
developed survival pathways that are independent of regulation
by ER. In otherwords, the pivotal role of the ER in growth has been
subverted by alternate survival and growth pathways. One
potential strategy could be to convert an endocrine nonresponsive
tumour to become responsive to oestrogen-induced apoptosis by
blocking the survival pathways with the expanding list of tyrosine
kinase inhibitors and antibodies that block cell surface signalling.
The goal would be to prevent cancer cell survival. This
pharmacological strategy might enhance the possibility that the
ER complex could initiate events which lead to apoptosis in the
vulnerable cells. There would also be the possibility that the
oestradiol ER complex could synergise with traditional inducers of
apoptosis, for example, chemotherapy in cells paralysed with select
cell survival inhibitors. All these options can be advanced in
clinical trial.
The ultimate goal of the basic research will be to identify the
molecular mechanism that permits the oestradiol ER complex to
switch from being a survival mechanism through replication to a
death signal. How does the ER complex know when it must induce
the death of an aberrant cell? Clues are already available since the
expression of ectopic ER in ER-negative cells prevents replication
(Jiang and Jordan, 1992) so the next step will be to identify critical
pathways in the ER-negative cell that can convert inhibition of
replication to the induction of apoptosis.
CONCLUSIONS
New knowledge about the ability of low concentrations of
oestrogens to cause apoptosis in exhaustively treated breast
tumour has the potential to advance targeted therapeutics not
only in breast cancer but also in other cancers. The remarkable
ability of the oestradiol ER complex, a natural signal-transduction
pathway, to discriminate between a growth and a death environ-
ment is unique. Application of the new knowledge has immediate
relevance for the treatment of metastatic breast cancer and the
eventual maintenance of breast cancer patients for decades using
cycles of antihormones, but with regular ‘oestrogen purges’ to kill
resistant cells, and subsequently reactivate antihormonal therapy.
Most importantly, the new knowledge will establish a strategic plan
to integrate novel survival blockers into a logical treatment
strategy and simultaneously utilise the emerging power of the
‘omics’ technologies to identify specific targets for future apoptotic
therapy.
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